HDM-FUN | Host directed medicine in invasive fungal infection

Summary
Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind.
The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care.
Specific objectives:
1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options.
2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis.
3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis.
4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals.
HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/847507
Start date: 01-01-2020
End date: 31-12-2024
Total budget - Public funding: 10 158 439,00 Euro - 9 998 170,00 Euro
Cordis data

Original description

Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind.
The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care.
Specific objectives:
1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options.
2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis.
3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis.
4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals.
HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.

Status

SIGNED

Call topic

SC1-BHC-14-2019

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2019-Two-Stage-RTD
SC1-BHC-14-2019 Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases